Published in Radiology on December 21, 2010
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers. BJU Int (2014) 1.75
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol (2014) 1.55
Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging (2013) 1.54
Diffusion Magnetic Resonance Imaging: What Water Tells Us about Biological Tissues. PLoS Biol (2015) 1.46
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med (2012) 1.34
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: optimal B value at 3T. Korean J Radiol (2012) 1.33
Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol (2011) 1.29
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int (2011) 1.26
Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int (2014) 1.18
Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol (2013) 1.17
What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T? Eur Radiol (2011) 1.13
The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol (2012) 0.99
The histogram analysis of diffusion-weighted intravoxel incoherent motion (IVIM) imaging for differentiating the gleason grade of prostate cancer. Eur Radiol (2014) 0.97
Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging (2014) 0.97
Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras (2015) 0.92
Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol (2012) 0.91
Correlated diffusion imaging. BMC Med Imaging (2013) 0.90
Advances in diffusion-weighted imaging. Radiol Clin North Am (2015) 0.89
The current and future role of magnetic resonance imaging in prostate cancer detection and management. Transl Androl Urol (2015) 0.89
Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol (2012) 0.88
Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software. BJU Int (2014) 0.86
Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer. Asian J Androl (2014) 0.85
Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol (2015) 0.85
MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Front Oncol (2015) 0.84
Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence. Magn Reson Imaging (2015) 0.84
Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol (2016) 0.84
Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.83
Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Eur Radiol (2013) 0.83
Functional MRI in prostate cancer detection. Biomed Res Int (2014) 0.83
Multi-Parametric MRI-Directed Focal Salvage Permanent Interstitial Brachytherapy for Locally Recurrent Adenocarcinoma of the Prostate: A Novel Approach. J Cancer (2013) 0.82
Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint. Quant Imaging Med Surg (2013) 0.82
Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging (2011) 0.81
Augmenting MRI-transrectal ultrasound-guided prostate biopsy with temporal ultrasound data: a clinical feasibility study. Int J Comput Assist Radiol Surg (2015) 0.81
Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. Am Soc Clin Oncol Educ Book (2016) 0.81
Current role of multiparametric magnetic resonance imaging for prostate cancer. Quant Imaging Med Surg (2015) 0.80
Oncologic Angiogenesis Imaging in the clinic---how and why. Imaging Med (2011) 0.80
DW-MRI in assessment of the hypoxic fraction, interstitial fluid pressure, and metastatic propensity of melanoma xenografts. BMC Cancer (2014) 0.79
Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdom Radiol (2016) 0.79
Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session. Diagn Interv Radiol (2014) 0.79
Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer (2016) 0.78
DWI of Prostate Cancer: Optimal b-Value in Clinical Practice. Prostate Cancer (2014) 0.78
Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol (2014) 0.78
Diagnosis and Monitoring of Prostatic Lesions: A Comparison of Three Modalities: Multiparametric MRI, Fusion MRI/Transrectal Ultrasound (TRUS), and Traditional TRUS. Cureus (2016) 0.78
Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer. World J Urol (2015) 0.78
Multiparametric MRI of the prostate: diagnostic performance and interreader agreement of two scoring systems. Br J Radiol (2016) 0.77
The Utility of Diffusion Weighted Imaging (DWI) Using Apparent Diffusion Coefficient (ADC) Values in Discriminating Between Prostate Cancer and Normal Tissue. Pol J Radiol (2014) 0.76
In vivo MRI virtual colonography in a mouse model of colon cancer. Nat Protoc (2014) 0.76
Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the evaluation of prostate cancer. World J Radiol (2015) 0.76
Is visual registration equivalent to semiautomated registration in prostate biopsy? Biomed Res Int (2015) 0.76
Radiologic presentation of chronic granulomatous prostatitis mimicking locally advanced prostate adenocarcinoma. Radiol Case Rep (2016) 0.75
PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. Expert Rev Precis Med Drug Dev (2016) 0.75
Relationship between Gleason score and apparent diffusion coefficients of diffusion-weighted magnetic resonance imaging in prostate cancer patients. Can Urol Assoc J (2016) 0.75
Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer. Br J Radiol (2016) 0.75
Impact of the use of an endorectal coil for 3 T prostate MRI on image quality and cancer detection rate. Sci Rep (2017) 0.75
Novel concepts for risk stratification in prostate cancer. J Clin Urol (2016) 0.75
Prostate biopsy for the interventional radiologist. J Vasc Interv Radiol (2014) 0.75
An imaging-based approach predicts clinical outcomes in prostate cancer through a novel support vector machine classification. Oncotarget (2016) 0.75
MRI-guided biopsies and minimally invasive therapy for prostate cancer. Indian J Urol (2015) 0.75
Magnetic resonance microscopy of prostate tissue: How basic science can inform clinical imaging development. J Med Radiat Sci (2013) 0.75
Prostate cancer: predicting tumor aggressiveness using DWI-guided biopsy. Nat Rev Urol (2011) 0.75
Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. Exp Biol Med (Maywood) (2014) 0.75
Improved Magnetic Resonance Imaging-Pathology Correlation With Imaging-Derived, 3D-Printed, Patient-Specific Whole-Mount Molds of the Prostate. Invest Radiol (2017) 0.75
Diffusion magnetic resonance imaging: A molecular imaging tool caught between hope, hype and the real world of "personalized oncology". World J Radiol (2017) 0.75
Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. Radiology (2017) 0.75
Amide proton transfer (APT) magnetic resonance imaging of prostate cancer: comparison with Gleason scores. MAGMA (2016) 0.75
Differentiation of prostate cancer lesions with high and with low Gleason score by diffusion-weighted MRI. Eur Radiol (2016) 0.75
Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging. Rev Urol (2017) 0.75
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging (1999) 4.94
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging (2002) 3.35
Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology (1996) 2.95
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol (2010) 1.91
Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int (2007) 1.86
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology (1999) 1.82
Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol (2008) 1.76
Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology (2007) 1.72
Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol (2009) 1.70
Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int (2008) 1.61
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology (2009) 1.55
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol (2006) 1.54
Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr (2007) 1.44
Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging (2008) 1.43
Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol (2008) 1.33
MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol (2009) 1.32
Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr (2005) 1.29
Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology (2007) 1.29
Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging (2007) 1.08
Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging (2009) 1.02
Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br J Radiol (2008) 1.01
Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T. Magn Reson Imaging (2007) 1.01
Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol (2005) 1.00
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int (2009) 0.94
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat Immunol (2011) 3.77
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol (2008) 3.30
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Navigation with electromagnetic tracking for interventional radiology procedures: a feasibility study. J Vasc Interv Radiol (2005) 2.67
The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science (2014) 2.63
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol (2010) 2.58
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology (2003) 2.53
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28
Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer. Cancer (2014) 2.27
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19